[(3S,4R,5R)-1,4,5,6-四羟基-2-氧代己烷-3-基]磷酸二氢酯 | 126247-74-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: [(3S,4R,5R)-1,4,5,6-四羟基-2-氧代己烷-3-基]磷酸二氢酯
• 中文别名: 果糖3-磷酸酯
• 英文名称: D-arabino-1,4,5,6-Tetrahydroxy-3-phosphonooxy-hexan-2-on
• 英文别名: O³-Phosphono-D-fructose；D-Fructose-3-phosphat；Fructose 3-phosphate；[(3S,4R,5R)-1,4,5,6-tetrahydroxy-2-oxohexan-3-yl] dihydrogen phosphate
• CAS: 126247-74-3
• 化学式: C₆H₁₃O₉P
• 分子量: 260.138
• InChiKey: NFKVQPCCMLVBGQ-UYFOZJQFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  165
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  O³-diphenoxyphosphoryl-O¹,O²;O⁴,O⁵-diisopropylidene-β-D-fructopyranose 在 乙醚 、 铂 作用下， 生成 [(3S,4R,5R)-1,4,5,6-四羟基-2-氧代己烷-3-基]磷酸二氢酯
  参考文献：
  名称：

  Brigl; Mueller, Chemische Berichte, 1939, vol. 72, p. 2121,2127

  摘要：

  DOI：

文献信息

• Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
  申请人：——

  公开号：US20020111291A1

  公开（公告）日：2002-08-15

  Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a contributing cause of diabetic complications. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications and the effects of glycogen storage diseases, including Fanconi's syndrome. Methods for assessing a diabetic's risk of developing complications and for determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product are also disclosed.

  本文披露了一类化合物，可以抑制酶催化将果糖赖氨酸转化为果糖赖氨酸-3-磷酸酯的反应，这是一种新发现的代谢途径中依赖ATP的反应。根据该途径的正常功能，果糖赖氨酸-3-磷酸酯（FL3P）被分解为游离赖氨酸、无机磷酸盐和3-脱氧葡萄糖酮（3DG），后者是一种具有反应性的蛋白质修饰剂。3DG可以通过还原为3-脱氧果糖（3DF）来解毒，也可以与内源蛋白质反应形成高级糖基化终产物修饰的蛋白质（AGE-蛋白），据信这是糖尿病并发症的一个促发因素。此外，还披露了使用这种抑制剂的治疗方法，以减少AGE-蛋白的形成，从而减轻、减少和延迟糖尿病并发症和糖原贮积病（包括范科尼综合征）的影响。还披露了通过在口服含果糖赖氨酸的食品后测量生物样品中3DG与3DF比值来评估糖尿病患者发生并发症的风险和确定披露的抑制剂疗法的疗效的方法。
• Fructoseamine 3 kinase and the formation of collagen and elastin
  申请人：Tobia Annette

  公开号：US20070065443A1

  公开（公告）日：2007-03-22

  The invention relates to the discovery that levels of collagen and elastin can be modulated by changing the flux through the Amadori Pathway and that copper containing compounds and complexes inhibit the enzyme fructoseamine-3-kinase.

  本发明涉及到一项发现，即通过改变Amadori途径的通量可以调节胶原蛋白和弹性蛋白的水平，并且含铜化合物和配合物可以抑制酶果糖胺-3-激酶。
• Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds
  申请人：Tobia Annette

  公开号：US20060110439A1

  公开（公告）日：2006-05-25

  The present invention relates to methods and compositions for the treatment of skin-related conditions and disorders. In one aspect, the invention features methods and compositions for the transdermal delivery of compounds for the treatment of skin-related conditions and disorders, wherein the compositions include meglumine and a liposome component.

  本发明涉及治疗皮肤相关疾病的方法和组合物。在一个方面，本发明的特点是用于治疗皮肤相关疾病的化合物透皮给药的方法和组合物，其中组合物包括麦格鲁明和脂质体成分。
• Nodzu, Journal of Biochemistry, 1926, vol. 6, p. 31,33
  作者：Nodzu

  DOI：——

  日期：——
• Raymond; Levene, Journal of Biological Chemistry, 1929, vol. 83, p. 619,622
  作者：Raymond、Levene

  DOI：——

  日期：——